Relmada posts topline data for lead asset in abuse potential trial against ketamine (RLMD)
The event stage biotech firm, Relmada Therapeutics (NASDAQ:RLMD) introduced on Wednesday the topline outcomes from the human abuse potential (HAP) examine for its lead candidate REL-1017, presently in Section 3 ...